|
| 36394838 | Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. | JAMA Oncol | 2023 |
| 36394838 | Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. | JAMA Oncol | 2023 |
| 37935104 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 38015376 | A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM). | J Neurooncol | 2023 |
| 37704607 | Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas. | Nat Commun | 2023 |
| 37961385 | A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). | Res Sq | 2023 |
| 37274750 | FAIR in action: Brain-CODE - A neuroscience data sharing platform to accelerate brain research. | Front Neuroinform | 2023 |
| 38015376 | A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM). | J Neurooncol | 2023 |
| 37961385 | A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). | Res Sq | 2023 |
| 37704607 | Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas. | Nat Commun | 2023 |
| 37935104 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 37274750 | FAIR in action: Brain-CODE - A neuroscience data sharing platform to accelerate brain research. | Front Neuroinform | 2023 |
| 35020109 | Radiomics for precision medicine in glioblastoma. | J Neurooncol | 2022 |
| 36069696 | Neurosurgery's Impact on Neuro-Oncology-"Can We Do Better?"-Lessons Learned Over 50 Years. | Neurosurgery | 2022 |
| 35212383 | Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors. | Neuro Oncol | 2022 |
| 35020109 | Radiomics for precision medicine in glioblastoma. | J Neurooncol | 2022 |
| 36069696 | Neurosurgery's Impact on Neuro-Oncology-"Can We Do Better?"-Lessons Learned Over 50 Years. | Neurosurgery | 2022 |
| 35212383 | Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors. | Neuro Oncol | 2022 |
| 33027815 | A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. | Neurosurgery | 2021 |
| 34014037 | Rapid real-world data analysis of patients with cancer, with and without COVID-19, across distinct health systems. | Cancer Rep (Hoboken) | 2021 |
| 33560371 | A serum-based DNA methylation assay provides accurate detection of glioma. | Neuro Oncol | 2021 |
| 33085768 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. | Neuro Oncol | 2021 |
| 33027815 | A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. | Neurosurgery | 2021 |
| 33560371 | A serum-based DNA methylation assay provides accurate detection of glioma. | Neuro Oncol | 2021 |
| 34014037 | Rapid real-world data analysis of patients with cancer, with and without COVID-19, across distinct health systems. | Cancer Rep (Hoboken) | 2021 |
| 33085768 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. | Neuro Oncol | 2021 |
| 32444980 | Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. | J Neurooncol | 2020 |
| 32064048 | Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. | Oncotarget | 2020 |
| 32444980 | Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. | J Neurooncol | 2020 |
| 32923886 | Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma. | JCO Precis Oncol | 2020 |
| 32064048 | Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. | Oncotarget | 2020 |
| 32923886 | Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma. | JCO Precis Oncol | 2020 |
| 30984233 | Big Data Needs Big Governance: Best Practices From Brain-CODE, the Ontario-Brain Institute's Neuroinformatics Platform. | Front Genet | 2019 |
| 31853198 | First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. | Cancer Manag Res | 2019 |
| 29982805 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. | Neuro Oncol | 2019 |
| 30131387 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. | Clin Cancer Res | 2019 |
| 30984233 | Big Data Needs Big Governance: Best Practices From Brain-CODE, the Ontario-Brain Institute's Neuroinformatics Platform. | Front Genet | 2019 |
| 31853198 | First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. | Cancer Manag Res | 2019 |
| 30131387 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. | Clin Cancer Res | 2019 |
| 29982805 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. | Neuro Oncol | 2019 |
| 29016998 | Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. | Neuro Oncol | 2018 |
| 29016998 | Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. | Neuro Oncol | 2018 |
| 29036345 | Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. | Neuro Oncol | 2018 |
| 29875648 | Brain-CODE: A Secure Neuroinformatics Platform for Management, Federation, Sharing and Analysis of Multi-Dimensional Neuroscience Data. | Front Neuroinform | 2018 |
| 29958537 | Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. | J Transl Med | 2018 |
| 29762717 | Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. | Neuro Oncol | 2018 |
| 29660005 | Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. | Neuro Oncol | 2018 |
| 29642018 | A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. | Cell Rep | 2018 |
| 29686388 | Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. | Nat Genet | 2018 |
| 29316430 | Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. | Cancer Cell | 2018 |